Motoharu Seiki

Title: Motoharu Seiki: Innovator in Cancer Diagnostics

Introduction

Motoharu Seiki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer diagnostics through his innovative patents. With a total of two patents to his name, Seiki's work focuses on elucidating molecular mechanisms that can enhance cancer treatment and diagnosis.

Latest Patents

Seiki's latest patents include a cancer examination method and examination kit. The objective of this invention is to clarify the molecular mechanism of ligand-independent activation of EphA2 in cancer cells. This advancement aims to make EphA2 a more effective target for cancer treatment. The cancer testing method involves measuring the amount of an EphA2 protein fragment, which has a molecular weight ranging from 30 kDa to 80 kDa, in samples derived from subjects. Additionally, he has developed methods for diagnosing hepatocellular carcinoma and pancreatic cancer. These methods utilize biomarkers such as laminin gamma 2 monomer, PIVKA-II, AFP, CEA, and CA19-9, which can be detected to diagnose, prognose, classify risk, and monitor the progression of these cancers.

Career Highlights

Throughout his career, Motoharu Seiki has worked with esteemed institutions, including the University of Tokyo and Abbott Japan LLC. His experience in these organizations has contributed to his expertise in cancer research and diagnostics.

Collaborations

Seiki has collaborated with notable colleagues, including Naohiko Koshikawa and Toru Yoshimura. Their joint efforts have further advanced the field of cancer diagnostics.

Conclusion

Motoharu Seiki's innovative work in cancer diagnostics highlights his commitment to improving cancer treatment and detection methods. His patents reflect a significant contribution to medical science, aiming to enhance patient outcomes in the fight against cancer.